ROS-responsive multifunctional DCS-based micelle hydrogel for simultaneously inhibiting post-resection melanoma...

Area of Science:

• Biomaterials Science
• Cancer Therapy
• Wound Healing

Background:

• Delayed healing of post-melanoma resection wounds can lead to tumor recurrence.
• Effective postoperative management requires simultaneous anti-cancer activity and wound healing promotion.

Purpose of the Study:

• To develop a multifunctional micelle hydrogel (AB@MH) for integrated post-resection melanoma therapy.
• To achieve controlled drug release, enhanced anti-tumor efficacy, and accelerated wound repair.

Main Methods:

• Fabrication of a dodecyl-modified chitosan (DCS)-based hydrogel co-loaded with apigenin and BMS-202 within ROS-responsive nanomicelles.
• Utilizing Schiff base linkages and hydrogen bonding for hydrogel formation.
• In vivo evaluation in a melanoma resection model.

Main Results:

• The AB@MH formulation demonstrated ROS-triggered drug release, minimizing systemic toxicity.
• Apigenin showed selective cytotoxicity against tumor cells and bacteria, inducing immunogenic cell death (ICD).
• Combined therapy with BMS-202 enhanced anti-tumor efficacy without harming normal cells.
• AB@MH significantly suppressed tumor recurrence and accelerated wound healing in vivo.

Conclusions:

• The developed AB@MH is a safe and effective multifunctional material for postoperative melanoma treatment.
• This approach successfully integrates anti-tumor therapy and wound healing enhancement.
• The study highlights a promising strategy for improving outcomes in post-resection cancer care.